Art. -Nr.: HY-B0374

Moxonidine

(Synonyms: BDF5895)

Kundenbewertung

Based on 1 Customer Validation

Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.72%
CAS. Nr.: 75438-57-2
Formel: C₉H₁₂ClN₅O
Molecular Weight:241.68

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Moxonidine Chemical Structure

CAS. Nr.: 75438-57-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen :

In Vitro

Moxonidine (10 μM; 48 h) prevents the mild reduction in cardiomyocyte viability/mitochondrial activity induced by IL-1β and TNF-α^[1].
Moxonidine (10 μM; 2 h) increases uptake of oxidised low-density lipoprotein in cultured vascular smooth muscle cells via α2 Adrenoceptors^[2].
Moxonidine (30 μM) inhibits voltage-dependent N-type Ca²⁺ current by activating imidazoline I₁ receptors in rat superior cervical ganglion neurons^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Moxonidine (18 mg/kg/day; p.o.; via drinking water) decreases atherosclerosis formation in the aortic arch and left common carotid artery of ApoE^-/- mice infused with Angiotensin II, associated with increased plasma lipid hydroperoxide levels^[2].
Moxonidine (100-1000 μg/kg; i.v.) causes dose-dependent hypotension and bradycardia in conscious wild-type mice^[4].
Moxonidine (3-6 mg/kg/day; subcutaneous implantation via osmotic minipumps; 21 days) dose-dependently suppresses myocardial infarction-induced sympathetic activation, and the high dose normalizes ventricular weight-body weight ratio and interstitial collagen in rats with myocardial infarction ^[5].
Moxonidine (20-80 nmol; intracerebroventricular injection into the fourth ventricle) dose-dependently lowers mean arterial pressure, heart rate and sympathetic outflow in conscious spontaneously hypertensive rats, with stronger effects than when injected into the lateral ventricle^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 75438-57-2
Appearance Solid
Molecular Weight 241.68
Formel C₉H₁₂ClN₅O
Color White to off-white
SMILES

CC1=NC(OC)=C(NC2=NCCN2)C(Cl)=N1
Synonyms

BDF5895
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (82.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1377 mL

20.6885 mL

41.3770 mL

5 mM

0.8275 mL

4.1377 mL

8.2754 mL

10 mM

0.4138 mL

2.0689 mL

4.1377 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (8.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2 mg/mL (8.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2 mg/mL (8.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (624 KB)
- English - EN (624 KB)
- Français - FR (624 KB)
- Deutsch - DE (624 KB)
- Norwegian - NO (624 KB)
- Español - ES (624 KB)
- Swedish - SV (624 KB)
- Italian - IT (624 KB)
- Korean - KR (624 KB)
- Portuguese - PT (624 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Aceros H, et al. Moxonidine modulates cytokine signalling and effects on cardiac cell viability. Eur J Pharmacol. 2014 Oct 5;740:168-82. [Content Brief]

[2]. Wang Y, et al. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023 Feb 14;24(4):3857. [Content Brief]

[3]. Kim YH, et al. Modulation of N-type Ca²⁺ currents by moxonidine via imidazoline I₁ receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011 Jun 17;409(4):645-50. [Content Brief]

[4]. Zhu QM, et al. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. [Content Brief]

[5]. Van Kerckhoven R, et al. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol. 2000 May 26;397(1):113-20. [Content Brief]

[6]. Nurminen ML, et al. Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 27;362(1):61-7. [Content Brief]

[7]. Tsutsui H, et al. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009 Jan 28;603(1-3):73-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1377 mL	20.6885 mL	41.3770 mL	103.4426 mL
	5 mM	0.8275 mL	4.1377 mL	8.2754 mL	20.6885 mL
	10 mM	0.4138 mL	2.0689 mL	4.1377 mL	10.3443 mL
	15 mM	0.2758 mL	1.3792 mL	2.7585 mL	6.8962 mL
	20 mM	0.2069 mL	1.0344 mL	2.0689 mL	5.1721 mL
	25 mM	0.1655 mL	0.8275 mL	1.6551 mL	4.1377 mL
	30 mM	0.1379 mL	0.6896 mL	1.3792 mL	3.4481 mL
	40 mM	0.1034 mL	0.5172 mL	1.0344 mL	2.5861 mL
	50 mM	0.0828 mL	0.4138 mL	0.8275 mL	2.0689 mL
	60 mM	0.0690 mL	0.3448 mL	0.6896 mL	1.7240 mL
	80 mM	0.0517 mL	0.2586 mL	0.5172 mL	1.2930 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Moxonidine

GPCR/G Protein Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Antidepressant Compound Library

Human Metabolite Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Moxonidine Related Classifications

HY-B0374 Related Classifications